findmyKOL
Clinical trialNCT07620548Not, yet, recruitingPhase 2Interventional

Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

SponsorWashington University School of MedicineEnrollment99GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeGlioblastoma, IDH-wildtype
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients will be enrolled and randomized on a 2:1 ratio to either the experimental arm (LiTT + cemiplimab) or the control arm (LiTT + physician/s choice chemotherapy).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic

    Rochester, Minnesota, United States

    Jian L Campian, M.D., Ph.D.
  • Washington University School of Medicine

    St Louis, Missouri, United States

    Albert H Kim, M.D., Ph.D.Dimitrios Mathios, M.D.Eric Leuthardt, M.D.Jingqin (Rosy) Luo, Ph.D.Milan Chheda, M.D.Omar H Butt, M.D., Ph.D.Tanner M Johanns, M.D., Ph.D.Yu (Jade) Tao, M.D.

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cemiplimab →Chemotherapy →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2026
Primary completion
28 Feb 2031
Completion
31 Aug 2032
Last update posted
2 Jun 2026
Registered enrollment
99
Registry id
NCT07620548
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.